This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

MDT Insights: When to choose ZEPATIER® (elbasvir/grazoprevir) as a treatment option for your HIV/HCV co-infected patients?

Patient Case Study: A patient with HIV/HCV co-infection

Prescribing Information

Length: 07:00

Dr Ahmed Elsharkawy
Consultant Hepatologist, Queen Elizabeth Hospital, Birmingham

Eleri Lougher
Hepatitis C ODN Lead Pharmacist, Queen Elizabeth Hospital, Birmingham

Sally Bufton
ODN Nurse Manager, Queen Elizabeth Hospital, Birmingham

This promotional video is fully funded and filmed by MSD.

More information about ZEPATIER® (elbasvir/grazoprevir):

Supporting documentation

GB-ZEP-00064 | Date of Preparation: February 2019